Osteoclasts are not a source of SLIT3.
Bone
Metabolism
Journal
Bone research
ISSN: 2095-4700
Titre abrégé: Bone Res
Pays: China
ID NLM: 101608652
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
03
2019
revised:
29
09
2019
accepted:
21
10
2019
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
The axon guidance cue SLIT3 was identified as an osteoanabolic agent in two recent reports. However, these reports conflict in their nomination of osteoblasts versus osteoclasts as the key producers of skeletal SLIT3 and additionally offer conflicting data on the effects of SLIT3 on osteoclastogenesis. Here, aiming to address this discrepancy, we found no observable SLIT3 expression during human or mouse osteoclastogenesis and the only modest SLIT3-mediated effects on osteoclast differentiation. Conditional deletion of SLIT3 in cathepsin K (CTSK)-positive cells, including osteoclasts, had no effect on the number of osteoclast progenitors, in vitro osteoclast differentiation, overall bone mass, or bone resorption/formation parameters. Similar results were observed with the deletion of SLIT3 in LysM-positive cells, including osteoclast lineage cells. Consistent with this finding, bone marrow chimeras made from
Identifiants
pubmed: 32133214
doi: 10.1038/s41413-020-0086-3
pii: 86
pmc: PMC7031526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR075585
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Genome Biol. 2014;15(12):550
pubmed: 25516281
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5217-22
pubmed: 12702769
Nature. 2013 May 23;497(7450):490-3
pubmed: 23644455
Blood. 2009 Nov 5;114(19):4300-9
pubmed: 19741192
Endocrinology. 2014 Oct;155(10):4015-26
pubmed: 25051436
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Neuron. 2004 Apr 22;42(2):213-23
pubmed: 15091338
J Clin Invest. 2015 Aug 3;125(8):3269-79
pubmed: 26193638
N Engl J Med. 2007 Aug 30;357(9):905-16
pubmed: 17761594
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Protoc. 2015 Dec;10(12):1904-14
pubmed: 26513669
J Clin Invest. 2018 Apr 2;128(4):1429-1441
pubmed: 29504949
Lancet. 2013 Jul 6;382(9886):50-6
pubmed: 23683600
Immunity. 2017 Jul 18;47(1):66-79.e5
pubmed: 28723554
J Clin Invest. 2013 Feb;123(2):666-81
pubmed: 23321671
Lancet. 2015 Sep 19;386(9999):1147-55
pubmed: 26144908
Nat Med. 2014 Nov;20(11):1270-8
pubmed: 25282358
Nat Med. 2009 Sep;15(9):1066-71
pubmed: 19718038
J Bone Miner Res. 2017 Sep;32(9):1811-1815
pubmed: 28561373
Nature. 2018 Oct;562(7725):133-139
pubmed: 30250253
Nat Med. 2011 Oct 23;17(11):1473-80
pubmed: 22019888
Cell Adh Migr. 2014;8(1):5-10
pubmed: 24589620
Nat Commun. 2018 Oct 5;9(1):4108
pubmed: 30291236
J Immunol. 2010 Dec 15;185(12):7691-8
pubmed: 21078908
Transgenic Res. 1999 Aug;8(4):265-77
pubmed: 10621974
Nat Med. 2018 Jun;24(6):823-833
pubmed: 29785024
Lab Invest. 2012 Aug;92(8):1129-39
pubmed: 22614124
J Exp Med. 2015 Jul 27;212(8):1283-301
pubmed: 26195726
N Engl J Med. 2016 May 26;374(21):2096-7
pubmed: 27223157
J Clin Invest. 2019 Mar 1;129(3):1076-1093
pubmed: 30530994
Br J Cancer. 2004 Dec 13;91(12):2071-8
pubmed: 15534609
J Biol Chem. 2018 Mar 2;293(9):3039-3055
pubmed: 29317497
Immunome Res. 2008 Apr 29;4:5
pubmed: 18442421
J Mol Cell Cardiol. 2013 Nov;64:124-31
pubmed: 24090675